Loading
The Charing Cross series that established EMA/CO, an alternating weekly combination of five drugs, as the standard treatment for high-risk gestational trophoblastic disease, curing more than eight in ten women.
Retrospective analysis of 272 women with high-risk gestational trophoblastic tumours treated at Charing Cross Hospital with EMA/CO (etoposide, methotrexate and dactinomycin alternating weekly with cyclophosphamide and vincristine) between 1979 and 1995.
Five-year survival was about 86 percent, with complete remission in most and salvage of many who relapsed or were resistant using platinum-containing regimens and surgery; early deaths from disease and secondary leukaemia after etoposide were noted.
EMA/CO remains the first-line regimen for high-risk GTN worldwide; later Charing Cross work added low-dose induction etoposide-cisplatin for women with very high scores.
Shares Dactinomycin (actinomycin D), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Methotrexate, Etoposide.
Shares Dactinomycin (actinomycin D), Methotrexate, Journal of Clinical Oncology.
Shares Methotrexate, Vincristine, Etoposide, Cyclophosphamide.
Shares Dactinomycin (actinomycin D), Vincristine, Cyclophosphamide.
Shares Dactinomycin (actinomycin D), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Methotrexate, Vincristine.
Shares Methotrexate, Vincristine, Etoposide, Cyclophosphamide.
Shares Dactinomycin (actinomycin D), Vincristine.
Shares Vincristine, Etoposide, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/